Galectin-3 and Placenta Accreta

Placenta Accreta Clinical Trial

Official title:

The Role of Galectin-3 in the Pathogenesis and Prediction of Placenta Accreta

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04573452
• Other study ID #: G-PA
• Status: Completed
• Start date: October 1, 2020
• Est. completion date: October 1, 2021

Study information

• Verified date: October 2022
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Galectins are a family of carbohydrate-binding proteins that have a high affinity to galactosides, its protein portion is located in the nucleus and the cytoplasm with its carbohydrate recognition domain which has high ability to be glycosylated inside or outside the cell.

They are expressed by vascular endothelium, immune cells (macrophages, neutrophils, and mast cells), uterus, placenta, cardiac muscle, liver, epithelium of the gastrointestinal tract, and many other tissues.

Although some galectins have intracellular functions, the majority of them have extracellular activities, which facilitate their contribution to cell adhesion, cell activation, and inflammation. Galectin-3 (Gal-3) is a unique pentamer of the galectins family and it is involved in both physiological functions; cell growth and differentiation, and pathological conditions; inflammation, fibrosis, and metastasis.

Regarding pregnancy, Gal-3 is proved to participate in angiogenesis, embryo developmental processes, and modulation of maternal immunity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: October 1, 2021
• Est. primary completion date: October 1, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Pregnant women between 28-32 weeks.

2. Age between 20-40 years.

3. Singleton pregnancy.

4. Women with suspicion of placenta accreta

5. Cases with mild vaginal bleeding or not having any vaginal bleeding.

Exclusion Criteria:

1. Women are known to have any medical disorders.

2. Patients with known bleeding disorders or on anticoagulant therapy.

3. Patients refuse to participate.

Related Conditions & MeSH terms

• Placenta Accreta

Intervention

Diagnostic Test:
• Galectin-3
Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R&D Systems, Minneapolis, MN, USA).
• Placental Galactin-3
Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA

Locations

Country	Name	City	State
Egypt	Women Health Hospital - Assiut university	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Galactin 3 level in the blood	measured by ng/ml	6 weeks